Rimegepant: A New Hope for Triptan-Unsuitable Migraine Relief

Research Summary

In a recent study published in Cephalalgia, researchers explored the effectiveness of rimegepant, a calcitonin gene-related peptide antagonist, for migraine sufferers unsuitable for triptans. This phase 4 trial involved 585 adults who could not use triptans due to intolerance, inefficacy, or contraindications. Participants took a single 75-mg dose of rimegepant or a placebo during a migraine attack. Findings showed that rimegepant significantly outperformed the placebo in achieving pain relief at two hours, with 55.9% experiencing relief compared to 32.7% in the placebo group. Additionally, rimegepant was well tolerated, with no severe side effects reported, suggesting it as a promising option for those who cannot take triptans.

Study Details

📄 Title: Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trial.

👥 Research Team: Ashina M et al.

📚 Published In: Cephalalgia

📅 Publication Date: 2025 Nov

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.